GRAIL Inc. (NASDAQ: GRAL) faces a securities fraud class action after its stock dropped 50.55% when the NHS-Galleri cancer trial failed its primary endpoint. The lead plaintiff deadline is Aug. 4, 2026.
Back
GRAIL sued for securities fraud after 50% stock drop on trial miss
A class action lawsuit hit GRAIL Inc. after its stock lost 50.55% in a single day when a key cancer trial missed its primary endpoint.
"The trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers," the complaint alleges, citing statements from GRAIL's own disclosures.
The lawsuit, filed in the U.S. District Court for the Northern District of California, covers investors who bought GRAIL common stock between May 13, 2025 and February 19, 2026. Shares closed at $101.53 on Feb. 19 before GRAIL announced that the NHS-Galleri trial — a multi-cancer early detection study conducted with the U.K.'s National Health Service — did not achieve its primary endpoint of a statistically significant reduction in late-stage cancers. The stock plunged $51.32 to $50.21 the next day.
The lead plaintiff deadline is Aug. 4, 2026. GRAIL, which was spun out of Illumina Inc., has not commented on the litigation. The failed trial raises questions about the commercial viability of the Galleri test as a national screening program.
The complaint alleges GRAIL made positive statements about the trial design and top-line results from the first screening round, including that the study was "designed with three consecutive years of screening in order to achieve the primary endpoint." In reality, the three-year timeframe was insufficient, according to the lawsuit.
GRAIL attributed the disappointing outcome in part to needing "a longer follow-up time" to adequately compare the two arms of the study. The company had also repeatedly declined to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing trendlines that suggested a longer timeline would be necessary.
Bleichmar Fonti & Auld LLP filed the class action. The Rosen Law Firm has also issued notices to investors, urging them to secure counsel before the August deadline.
The 50% collapse erased roughly $3 billion in market value from GRAIL, which went public via a SPAC merger in 2021. Investors will watch for any further disclosures from the company and whether the NHS extends or restructures the trial. The next catalyst is the lead plaintiff deadline on Aug. 4, which will determine who directs the litigation.
This article is for informational purposes only and does not constitute investment advice.
[1] $GRAL Fraud Notification: GRAIL, Inc. Sued for Securities Fraud After Trial Results Spark a 50% Stock Drop – Investors Notified to Contact BFA Law by August 4[2] GRAIL: FDA Approval Could Unlock Vast Potential[3] ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before ...[4] $GRAL Fraud Notification: GRAIL, Inc. Sued for Securities - GlobeNewswire[5] GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit - PR Newswire
